Equibles does not estimate personal net worth.
Get an email with a short summary when Gilead Sciences, Inc. publishes a filing, an earnings call transcript or a press release.
Get GILD alertsDietmar Berger is recorded as Board Member at Arcus Biosciences, Inc. (RCUS). The newest filing on record that lists Dietmar Berger as Board Member at Arcus Biosciences, Inc. (RCUS) is dated April 21, 2026. The proxy statement of Gilead Sciences, Inc. reports total compensation of $13,922,878 for Dietmar Berger in fiscal 2025, including a base salary of $969,231. Disclosed compensation is on record for 2 fiscal years. Dietmar Berger has spoken on 4 earnings calls and 2 other investor events across 1 company, most recently for Gilead Sciences, Inc. on August 4, 2026. Gilead Sciences, Inc. is classified in the Drug Manufacturers - General industry within the Healthcare sector. Arcus Biosciences, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Gilead Sciences, Inc. includes Daniel P. O’Day (CEO), Robin L. Washington (CFO), Diane E. Wilfong (Chief Accounting Officer) and 7 others.
“We delivered another strong quarter of clinical execution across our 53 ongoing clinical programs, reflecting both the continued growth of our pipeline and our disciplined approach to portfolio prioritization.”
“Tridelby is obviously our drop-2 ADC, where we had positive data recently in first-line triple-negative breast cancer. That's the Ascent 3 and O4 study. And that's where we're looking forward also to hopefully get an approval later this year for that setting.”
“Today, Gilead has the strongest and most diversified pipeline in our history, with meaningful progress across our virology, oncology, and inflammation programs.”
“I'd like to start on slide 16 by recognizing the years of tireless effort across many research and development teams at Gilead, KITE, and our partners that contributed to a spectacular quarter of clinical results.”
“We have made a lot of progress in the first quarter with some exciting Lenacapivir updates at CROI and our first pivotal phase 3 top-line readout for Trodelby in breast cancer since 2022.”
Source not stated
Start not stated–present
Last confirmed April 21, 2026
Proxy statement
Start not stated–2020-04-22
Last confirmed by a filing; no departure on record
Drug Manufacturers - General · Healthcare
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Gilead Sciences, Inc. (GILD) | M.D., Ph.D. Chief Medical Officer | $969,231 | $13,922,878 |
| 2018 | Atara Biotherapeutics, Inc. (ATRA) | M.D., Ph.D. Former Global Head of Research & Development | $320,385 | $4,972,439 |
